Resolute zotarolimus-eluting coronary stent implantation in Asian patients with multivessel disease and long lesions: clinical outcomes in RESOLUTE Asia

Two thirds of patients treated with drug-eluting stents (DES) for coronary artery disease in all-comers studies underwent percutaneous coronary intervention (PCI) of complex lesions. Long lesions (>18 mm) and multivessel treatment accounted for 20% and 60% of patients in the RESOLUTE All Comers study, respectively. Longer stent length is associated with higher risk for restenosis. In a study comparing single-vessel and multivessel treatment with DES, the six-month incidence of major adverse cardiac events was more than double among patients undergoing multivessel stenting6. The objective of the RESOLUTE Asia (R-Asia) study is to assess outcomes in Asian patients treated with the Resolute™ zotarolimus- eluting stent (R-ZES; Medtronic Inc., Santa Rosa, CA, USA) for multivessel treatment (R-Asia Dual Vessel cohort) and in long lesions (R-Asia 38 mm cohort).

The pooled one-year outcomes of patients treated with the 38 mm R-ZES in the R-Asia 38 mm cohort and the RESOLUTE US (R-US) 38 mm cohort (n=269) have been previously published. Target lesion failure (TLF) at one year was 5.4% and comprised 1.4% clinically driven target lesion revascularisation (TLR), 0.9% cardiac death, and 3.6% target vessel myocardial infarction (MI). Outcomes in the R-Asia Dual Vessel cohort have not been published.